Prospective observational study of febrile neutropenia (FN) and pegfilgrastim primary prophylaxis in breast cancer and non-Hodgkin’s lymphoma patients receiving high (>20%) FN-risk chemotherapy
Study Details
To estimate the incidence of febrile neutropenia in patients with breast cancer and non-Hodgkin’s lymphoma receiving high (> 20%) FN-risk chemotherapy and pegfilgrastim primary prophylaxis.
Protocol Summary
To estimate the incidence of FN in all subjects
Timeframe: Participants will be followed up for a maximum of 8 cycles of chemotherapy, an average observation period would be around 18 weeks.
To describe discontinuation of pegfilgrastim prophylaxis and discontinuation of G-CSF prophylaxis in terms of reasons and frequency of subjects and cycles
Timeframe: Participants will be followed up for a maximum of 8 cycles of chemotherapy, an average observation period would be around 18 weeks.
To estimate the incidence of complications of FN in all subjects across all cycles
Timeframe: Participants will be followed up for a maximum of 8 cycles of chemotherapy, an average observation period would be around 18 weeks.
To estimate the incidence of FN and complications of FN in discontinuation of G-CSF prophylaxis cycles at the subject and cycle level
Timeframe: Participants will be followed up for a maximum of 8 cycles of chemotherapy, an average observation period would be around 18 weeks.
To estimate the frequency of switch from pegfilgrastim prophylaxis to other G-CSF(s)
Timeframe: Participants will be followed up for a maximum of 8 cycles of chemotherapy, an average observation period would be around 18 weeks.